Tetraphase Pharmaceuticals Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2020 | $10 M | No. 3 | $10 to $50 million | equity, options | SEC | |
| May 2010 | $45 M | No. 2 | $10 to $50 million | equity | SEC | |
| Sep 2009 | $10 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Tetraphase Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2020).
SEC Form D · Jan 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jan 2020
That is all the official record says: Tetraphase Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: the website on record does not name the company, so it was not used.
Investors#
23 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| CMEA Ventures VI GmbH & Co. KG | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Cmea Ventures VI LP | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| CMEA Ventures VI Management, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| David Charles Lubner | Person | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Excel Medical Fund LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Excel Medical Ventures, LLC | Venture capital | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Flagship Ventures 2007 General Partner LLC | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Flagship Ventures Fund 2004 L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Flagship Ventures Fund 2007, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Flagship Ventures General Partner LLC | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Fmr LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Joaquim Trias | Person | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Mediphase (DP&UP) LLC | Other | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Mediphase II (Annex Fund) LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Mediphase II LLC | Other | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Mediphase II (Select Fund) LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Mediphase Venture Partners (DP&UP) Limited Partnership | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Mediphase Venture Partners II (Annex Fund) Limited Partnership | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Mediphase Venture Partners II LP | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred (Form 3, 2013) | SEC Form 3 |
| Mediphase Venture Partners II (Select Fund) Limited Partnership | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Skyline Venture Management IV, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Skyline Venture Partners Qualified Purchaser Fund IV L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Xiao-Yi Xiao | Person | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 14 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Christopher Watt | Executive officer | Jan 2020 |
| Larry Edwards | Executive officer | Jan 2020 |
| Maria Stahl | Executive officer | Jan 2020 |
| David Lubner | Executive officer | May 2010 |
| Guy Macdonald | Executive officer | May 2010 |
| Garen Patrick Bohlin | Director | Jan 2020 |
| Gerri G. Henwood | Director | Jan 2020 |
| Guy G. Macdonald | Director | Jan 2020 |
| Jeffrey A. Chodakewitz | Director | Jan 2020 |
| John G. Freund | Director | Jan 2020 |
| Keith G. Maher | Director | Jan 2020 |
| L. Patrick Gage | Director | Jan 2020 |
| Larry Edwards | Director | Jan 2020 |
| Nancy J. Wysenski | Director | Jan 2020 |
| Steven Patrick Boyd | Director | Jan 2020 |
| Douglas Cole | Director | May 2010 |
| Eric M. Gordon | Director | May 2010 |
| Guy Macdonald | Director | May 2010 |
| Karl D. Handelsman | Director | May 2010 |
| Lawrence Miller | Director | May 2010 |
| Robert D. Weisskoff | Director | May 2010 |
| Steve D. Gullans | Director | May 2010 |
| Robert Weisskoff | Director | Sep 2009 |
About
Company in Watertown, United States.